Multisystem Inflammatory Syndrome in Children (MIS-C)MUSICNCT05287412
Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children
An observational study of Multisystem Inflammatory Syndrome in Children (MIS-C), run by Carelon Research at 33 sites in 2 countries.
Trial summary
Multi-system Inflammatory Syndrome in Children (MIS-C) is a new condition related to COVID-19, the study investigators are still learning about its causes, effects, and long-term impact. Read more about this study
- Who is it for?
- Ages Up to 21 years
- Conditions the study is for
- Multisystem Inflammatory Syndrome in Children (MIS-C)
- How many people
- 1,200 participants
- Where
- 33 sitesin 2 countries
- Study dates
- 30 Sep 2020to 31 Jul 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 21 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: children and young adults <21 years with Multisystem Inflammatory Syndrome in Children associated with COVID-19 (MIS-C) at a participating hospital
Who may be able to join
- Age <21 years.
- Fever ≥38°C for ≥24 hours, or report of subjective fever lasting ≥24 hours.
- Laboratory evidence of inflammation, including, but not limited to, one or more of the following: an elevated CRP, ESR, fibrinogen, procalcitonin, d-dimer, ferritin, LDH, or IL-6, elevated neutrophils, reduced lymphocytes and low albumin.
- Evidence of clinically severe illness requiring hospitalization, with multisystem (≥2) organ involvement, based on clinical judgment from record review, discharge diagnosis, laboratory or diagnostic tests. Organ system involvement includes but is not limited to cardiac, renal, respiratory, hematologic including coagulopathy, gastrointestinal including liver, dermatologic or neurological.
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms
Who cannot join
- No plausible alternative diagnosis, such as bacterial sepsis, murine typhus, staphylococcal or streptococcal shock syndromes
Trial locations and contacts
33 sites in 2 countries.
33 sites in 2 countries
United States32 sites
CS Mott Children's Hospital/University of Michigan
Ann Arbor, Michigan, 48109
Chldren's Healthcare of Atlanta
Atlanta, Georgia, 30322
Children's Hospital of Colorado
Aurora, Colorado, 80045
Dell Medical Center
Austin, Texas, 78707
Boston Children's Hospital
Boston, Massachusetts, 02115
University of North Carolina
Chapel Hill, North Carolina, 27514
Medical University of South Carolina
Charleston, South Carolina, 29425
Ann & Robert Lurid Children's Hospital of Chicago
Chicago, Illinois, 60611
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
Children's Medical Center of Dallas - UT Southwestern Medical Center
Dallas, Texas, 75235
Children's Hospital of Michigan
Detroit, Michigan, 48201
Duke Children's Hospital and Health Center
Durham, North Carolina, 27705
Joe DiMaggio Children's Hospital
Hollywood, Florida, 33021
Baylor /Texas Children's Hospital
Houston, Texas, 77030
Riley Children's Hospital
Indianapolis, Indiana, 46202
University of Mississippi
Jackson, Mississippi, 39216
Children's Mercy Hospital
Kansas City, Missouri, 64108
Children's Hospital Los Angeles
Los Angeles, California, 90027
Valley Children's Healthcare and Hospital
Madera, California, 93636
Nicklaus Children's Hospital
Miami, Florida, 33155
Medical College of Wisconsin/Children's Hospital of Wisconsin
Milwaukee, Wisconsin, 53226
Children's Hospital of New Orleans
New Orleans, Louisiana, 70118
Morgan Stanley Children's Hospital of New York
New York, New York, 10032
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
Phoenix Children's Hospital
Phoenix, Arizona, 85016
Cohen Children's Medical Center
Queens, New York, 11040
Primary Children's Hospital
Salt Lake City, Utah, 84113
UC San Diego, Rady Children's Hospital
San Diego, California, 92131
Seattle Children's Hospital
Seattle, Washington, 98105
University of Alabama
Tuscaloosa, Alabama, 35401
Children's National Hospital
Washington D.C., District of Columbia, 20010
The Nemours Foundation
Wilmington, Delaware, 19808
About this study
Multi-system Inflammatory Syndrome in Children (MIS-C) is a new condition related to COVID-19, the study investigators are still learning about its causes, effects, and long-term impact. "Long-Term Outcomes after the Multisystem Inflammatory Syndrome In Children", the Coronavirus MUSIC Study, is a research study funded by NIH and the National Heart, Lung, and Blood Institute. The study investigators hope to enroll at least 900 young people with MIS-C at children's medical centers in the U.S. and Canada. This research study will help us learn more about MIS-C and its effects on the long-term health of children.
Read the detailed description
This study is an observational cohort study that will use routinely collected clinical and cardiac (EKG, echocardiogram, Cardiac MRI, exercise testing) data to assess the association between MIS-C and cardiac outcomes within the first year after hospital discharge. Research funding will be available for EKGs, echocardiograms and MRIs in protocol windows that are not ordered by primary caregivers. The principal goal is to determine the spectrum and early time course of coronary artery involvement, LV systolic function, and arrhythmias or conduction system abnormalities, and, using these data, to define associated clinical and laboratory factors. The study investigators planned to include all eligible patients, including retrospective cases beginning January 1, 2020, with follow-up (in-person or telehealth) to up within one year and annual medical history forms until up to 5 years have elapsed since illness onset. Because many patients will have been identified by retrospective review, the study team will obtain consent at different times in their illness course. For this reason, it may be hard to reach some patients and their families. Waiver of consent will be obtained after three attempts have been made to locate the patient and family without success, as well as for the rare child who dies before informed consent can be obtained. The study investigators will include a HIPAA-compliant cryptographic algorithm to create a sharable "hashed" identifier from patient information. If blood work for research purposes is added on to usual clinically indicated blood work during follow-up visits, this will be covered by other informed consent forms.
- Keywords
- COVID
- Medical subject headings
- pediatric multisystem inflammatory disease, COVID-19 related
What is being measured
The primary outcome is the main question the study is designed to answer.
worst-ever LV ejection fraction
worst left ventricular (LV) ejection fraction from core lab echo read during MUSIC study
Measured: hospital admission through 5 years post-hospitalization
worst-ever maximum z score of the proximal LAD or RCA
worst maximum z-score of the proximal left anterior descending coronary artery (LAD) or right coronary artery (RCA) from core lab echo read; z-scores to be calculated via Boston z-score calculator (primary) and Pediatric Heart Network z-score calculator (secondary); higher z-scores are worse
Measured: hospital admission through 5 years post-hospitalization
Secondary outcomes (34)
Occurrence of a proximal LAD or RCA z score of ≥2.5 on any echocardiogram
proximal left anterior descending coronary artery (LAD) or right coronary artery (RCA) ≥2.5 from any core lab echo read
Measured: hospital admission through 5 years post-hospitalization
Occurrence of aneurysms by Japanese Ministry of Health criteria
Occurrence of aneurysms by Japanese Ministry of Health criteria applied to core lab echo reads
Measured: hospital admission through 5 years post-hospitalization
Individual z scores for LMCA, RCA and LAD
Individual z scores for left main coronary artery (LMCA), right coronary artery (RCA) and proximal left anterior descending coronary artery (LAD) as per core lab echo reads; higher z-scores are worse
Measured: hospital admission through 5 years post-hospitalization
LVEDV z score
left ventricular (LV) size as measured by left ventricular end-diastolic volume (LVEDV) z score
Measured: hospital admission through 5 years post-hospitalization
LVEF
left ventricular (LV) function as measured by left ventricular ejection fraction (LVEF)
Measured: hospital admission through 5 years post-hospitalization
LVSF
left ventricular (LV) function as measured by left ventricular shortening fraction (LVSF)
Measured: hospital admission through 5 years post-hospitalization
The percentage of patients who had LV ejection of <55%, and further categorization of 45-54% (i.e., mildly depressed systolic function), 35-44% (moderately depressed systolic function) and <35% (severely depressed systolic function) on any echocardiogram
The percentage of patients who had left ventricular (LV) ejection of <55%, and further categorization of 45-54% (i.e., mildly depressed systolic function), 35-44% (moderately depressed systolic function) and <35% (severely depressed systolic function) on any echocardiogram read by the core lab
Measured: hospital admission through 5 years post-hospitalization
LV strain (global longitudinal strain from apical view and global circumferential strain from parasternal short-axis view)
left ventricular (LV) strain (global longitudinal strain from apical view and global circumferential strain from parasternal short-axis view) on core lab echo read
Measured: hospital admission through 5 years post-hospitalization
Qualitative assessment of RV systolic function
Qualitative assessment of right ventricular (RV) systolic function on core lab echo read
Measured: hospital admission through 5 years post-hospitalization
Qualitative assessment of RV global longitudinal strain
Qualitative assessment, if possible, of right ventricular (RV) global longitudinal strain on core lab echo read
Measured: hospital admission through 5 years post-hospitalization
Presence and degree of mitral and aortic regurgitation
Presence and degree of mitral and aortic regurgitation on echo core lab read
Measured: hospital admission through 5 years post-hospitalization
LV diastolic function, i.e., tissue Doppler imaging and mitral valve (MV) inflow
left ventricular (LV) diastolic function, i.e., tissue Doppler imaging and mitral valve (MV) inflow on echo core lab read
Measured: hospital admission through 5 years post-hospitalization
Presence and size of pericardial effusion
Presence and size of pericardial effusion on echo core lab read
Measured: hospital admission through 5 years post-hospitalization
The occurrence of arrhythmias and conduction system disturbances by in-hospital monitoring, electrocardiograms, and exercise testing at 3 months in those with a history of ≥moderate systolic dysfunction when age and maturity permit
The occurrence of arrhythmias and conduction system disturbances by in-hospital monitoring, electrocardiograms, and exercise testing at 3 months in those with a history of ≥moderate systolic dysfunction when age and maturity permit
Measured: 3 months post-discharge
MRI LVEF
LVEF on MRI core lab read
Measured: hospital admission through 5 years post-hospitalization
MRI RVEF
RVEF on MRI core lab read
Measured: hospital admission through 5 years post-hospitalization
valvar regurgitation
valvar regurgitation on MRI core lab read
Measured: hospital admission through 5 years post-hospitalization
myocardial late gadolinium enhancement (LGE)
percent with and distribution of myocardial late gadolinium enhancement (LGE) on MRI core lab read
Measured: hospital admission through 5 years post-hospitalization
abnormal T2-weighted imaging
percent abnormal T2-weighted imaging on MRI core lab read
Measured: hospital admission through 5 years post-hospitalization
elevated T2
percent with elevated T2 on MRI core lab read
Measured: hospital admission through 5 years post-hospitalization
elevated native T1
percent with elevated native T1 on MRI core lab read
Measured: hospital admission through 5 years post-hospitalization
elevated extracellular volume fraction
percent with elevated extracellular volume fraction on MRI core lab read
Measured: hospital admission through 5 years post-hospitalization
coronary artery dilation
percent with coronary artery dilation on MRI core lab read
Measured: hospital admission through 5 years post-hospitalization
CMR abnormal, equivocal, or negative
final interpretation of CMR as abnormal, equivocal, or negative (i.e., no abnormal or equivocal findings) on MRI core lab read
Measured: hospital admission through 5 years post-hospitalization
Other organ abnormalities by medical history: Immunologic, rheumatologic, renal, pulmonary, hematologic, gastrointestinal, dermatologic or neurologic
percent with other organ abnormalities by medical history: Immunologic, rheumatologic, renal, pulmonary, hematologic, gastrointestinal, dermatologic or neurologic
Measured: hospital admission through 5 years post-hospitalization
CRP
C-Reactive Protein (CRP) as a laboratory marker of inflammation
Measured: hospital admission through 5 years post-hospitalization
Admission to ICU
percent with admission to ICU
Measured: hospital admission through 5 years post-hospitalization
Maximal vasoactive inotrope score
Maximal vasoactive inotrope score
Measured: from MIS-C hospital admission to MIS-C hospital discharge
Hospital length of stay
Hospital length of stay
Measured: from MIS-C hospital admission to MIS-C hospital discharge
Symptom duration
Symptom duration
Measured: hospital admission through 5 years post-hospitalization
Major medical events
percent with major medical events (e.g., stroke, need for extracorporeal therapies such as renal replacement therapy, plasma exchange, ECMO, VAD)
Measured: hospital admission through 5 years post-hospitalization
Mortality
Percent mortality
Measured: hospital admission through 5 years post-hospitalization
Global Health - FSS
Global Health as measured by Functional Status Score [FSS]: range 6-30, lower is better
Measured: hospital admission through 5 years post-hospitalization
Global Health - PROMIS
Global Health as measured by Parent-Reported Outcomes Measurement Information Systems [PROMIS] Instrument: range 7-35, higher is better
Measured: hospital admission through 5 years post-hospitalization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2022
- Study start30 Sep 2020
- Primary completion31 Jul 2026 (estimated)
- Study completion31 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Multisystem Inflammatory Syndrome in Children (MIS-C)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,200 participants (actual)
Sponsor and investigators
- Lead sponsor
- Carelon Research
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05287412
- Sponsor's protocol ID
- G20479
- Acronym
- MUSIC
- Status last verified
- Mar 2026
- First submitted
- 9 Feb 2022
- Last updated
- 27 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Lang SM, Truong DT, Powell AJ, Kazlova V, Newburger JW, Awerbach JD, Binka E, Bradford TT, Cartoski M, Cheng A, DiLorenzo MP, Dionne A, Dorfman AL, Elias MD, Garuba O, Gerardin JF, Hasbani K, Jone PN, Lam CZ, Misra N, Morgan LM, Nutting A, Patel JK, Robinson JD, Schuchardt EL, Sexson Tejtel K, Singh GK, Slesnick TC, Trachtenberg F, Taylor MD; MUSIC Study Investigators. CMR Findings in the Long-Term Outcomes After Multisystem Inflammatory Syndrome in Children (MUSIC) Study. Circ Cardiovasc Imaging. 2025 Sep;18(9):e017420. doi: 10.1161/CIRCIMAGING.124.017420. Epub 2025 Apr 4.
PubMed 40181776
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children
- ClinicalTrials.gov ID
- NCT05287412
- Acronym / sponsor ID
- MUSIC / G20479
- Keywords
- COVID
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,200 participants (actual)
- Lead sponsor
- Carelon ResearchUniversity, hospital or other
- Study start
- 30 Sep 2020 (actual)
- Primary completion
- 31 Jul 2026 (estimated)
- Study completion
- 31 Jul 2026 (estimated)
- First posted
- 18 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Multi-system Inflammatory Syndrome in Children (MIS-C) is a new condition related to COVID-19, the study investigators are still learning about its causes, effects, and long-term impact. "Long-Term Outcomes after the Multisystem Inflammatory Syndrome In Children", the Coronavirus MUSIC Study, is a research study funded by NIH and the National Heart, Lung, and Blood Institute. The study investigators hope to enroll at least 900 young people with MIS-C at children's medical centers in the U.S. and Canada. This research study will help us learn more about MIS-C and its effects on the long-term health of children.
Detailed description
This study is an observational cohort study that will use routinely collected clinical and cardiac (EKG, echocardiogram, Cardiac MRI, exercise testing) data to assess the association between MIS-C and cardiac outcomes within the first year after hospital discharge. Research funding will be available for EKGs, echocardiograms and MRIs in protocol windows that are not ordered by primary caregivers. The principal goal is to determine the spectrum and early time course of coronary artery involvement, LV systolic function, and arrhythmias or conduction system abnormalities, and, using these data, to define associated clinical and laboratory factors. The study investigators planned to include all eligible patients, including retrospective cases beginning January 1, 2020, with follow-up (in-person or telehealth) to up within one year and annual medical history forms until up to 5 years have elapsed since illness onset. Because many patients will have been identified by retrospective review, the study team will obtain consent at different times in their illness course. For this reason, it may be hard to reach some patients and their families. Waiver of consent will be obtained after three attempts have been made to locate the patient and family without success, as well as for the rare child who dies before informed consent can be obtained. The study investigators will include a HIPAA-compliant cryptographic algorithm to create a sharable "hashed" identifier from patient information. If blood work for research purposes is added on to usual clinically indicated blood work during follow-up visits, this will be covered by other informed consent forms.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- Up to 21 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- children and young adults <21 years with Multisystem Inflammatory Syndrome in Children associated with COVID-19 (MIS-C) at a participating hospital
Key inclusion criteria (5 listed)
- Age <21 years.
- Fever ≥38°C for ≥24 hours, or report of subjective fever lasting ≥24 hours.
- Laboratory evidence of inflammation, including, but not limited to, one or more of the following: an elevated CRP, ESR, fibrinogen, procalcitonin, d-dimer, ferritin, LDH, or IL-6, elevated neutrophils, reduced lymphocytes and low albumin.
- Evidence of clinically severe illness requiring hospitalization, with multisystem (≥2) organ involvement, based on clinical judgment from record review, discharge diagnosis, laboratory or diagnostic tests. Organ system involvement includes but is not limited to cardiac, renal, respiratory, hematologic including coagulopathy, gastrointestinal including liver, dermatologic or neurological.
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms
Key exclusion criteria (1 listed)
- No plausible alternative diagnosis, such as bacterial sepsis, murine typhus, staphylococcal or streptococcal shock syndromes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
worst-ever LV ejection fraction
Time frame: hospital admission through 5 years post-hospitalization
worst left ventricular (LV) ejection fraction from core lab echo read during MUSIC study
worst-ever maximum z score of the proximal LAD or RCA
Time frame: hospital admission through 5 years post-hospitalization
worst maximum z-score of the proximal left anterior descending coronary artery (LAD) or right coronary artery (RCA) from core lab echo read; z-scores to be calculated via Boston z-score calculator (primary) and Pediatric Heart Network z-score calculator (secondary); higher z-scores are worse
34 secondary outcomes
Occurrence of a proximal LAD or RCA z score of ≥2.5 on any echocardiogram
Time frame: hospital admission through 5 years post-hospitalization
Occurrence of aneurysms by Japanese Ministry of Health criteria
Time frame: hospital admission through 5 years post-hospitalization
Individual z scores for LMCA, RCA and LAD
Time frame: hospital admission through 5 years post-hospitalization
LVEDV z score
Time frame: hospital admission through 5 years post-hospitalization
LVEF
Time frame: hospital admission through 5 years post-hospitalization
LVSF
Time frame: hospital admission through 5 years post-hospitalization
The percentage of patients who had LV ejection of <55%, and further categorization of 45-54% (i.e., mildly depressed systolic function), 35-44% (moderately depressed systolic function) and <35% (severely depressed systolic function) on any echocardiogram
Time frame: hospital admission through 5 years post-hospitalization
LV strain (global longitudinal strain from apical view and global circumferential strain from parasternal short-axis view)
Time frame: hospital admission through 5 years post-hospitalization
Qualitative assessment of RV systolic function
Time frame: hospital admission through 5 years post-hospitalization
Qualitative assessment of RV global longitudinal strain
Time frame: hospital admission through 5 years post-hospitalization
Presence and degree of mitral and aortic regurgitation
Time frame: hospital admission through 5 years post-hospitalization
LV diastolic function, i.e., tissue Doppler imaging and mitral valve (MV) inflow
Time frame: hospital admission through 5 years post-hospitalization
Presence and size of pericardial effusion
Time frame: hospital admission through 5 years post-hospitalization
The occurrence of arrhythmias and conduction system disturbances by in-hospital monitoring, electrocardiograms, and exercise testing at 3 months in those with a history of ≥moderate systolic dysfunction when age and maturity permit
Time frame: 3 months post-discharge
MRI LVEF
Time frame: hospital admission through 5 years post-hospitalization
MRI RVEF
Time frame: hospital admission through 5 years post-hospitalization
valvar regurgitation
Time frame: hospital admission through 5 years post-hospitalization
myocardial late gadolinium enhancement (LGE)
Time frame: hospital admission through 5 years post-hospitalization
abnormal T2-weighted imaging
Time frame: hospital admission through 5 years post-hospitalization
elevated T2
Time frame: hospital admission through 5 years post-hospitalization
elevated native T1
Time frame: hospital admission through 5 years post-hospitalization
elevated extracellular volume fraction
Time frame: hospital admission through 5 years post-hospitalization
coronary artery dilation
Time frame: hospital admission through 5 years post-hospitalization
CMR abnormal, equivocal, or negative
Time frame: hospital admission through 5 years post-hospitalization
Other organ abnormalities by medical history: Immunologic, rheumatologic, renal, pulmonary, hematologic, gastrointestinal, dermatologic or neurologic
Time frame: hospital admission through 5 years post-hospitalization
CRP
Time frame: hospital admission through 5 years post-hospitalization
Admission to ICU
Time frame: hospital admission through 5 years post-hospitalization
Maximal vasoactive inotrope score
Time frame: from MIS-C hospital admission to MIS-C hospital discharge
Hospital length of stay
Time frame: from MIS-C hospital admission to MIS-C hospital discharge
Symptom duration
Time frame: hospital admission through 5 years post-hospitalization
Major medical events
Time frame: hospital admission through 5 years post-hospitalization
Mortality
Time frame: hospital admission through 5 years post-hospitalization
Global Health - FSS
Time frame: hospital admission through 5 years post-hospitalization
Global Health - PROMIS
Time frame: hospital admission through 5 years post-hospitalization
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
- Derived from this study: PubMed 40181776Lang SM, Truong DT, Powell AJ, Kazlova V, Newburger JW, Awerbach JD, Binka E, Bradford TT, Cartoski M, Cheng A, DiLorenzo MP, Dionne A, Dorfman AL, Elias MD, Garuba O, Gerardin JF, Hasbani K, Jone PN, Lam CZ, Misra N, Morgan LM, Nutting A, Patel JK, Robinson JD, Schuchardt EL, Sexson Tejtel K, Singh GK, Slesnick TC, Trachtenberg F, Taylor MD; MUSIC Study Investigators. CMR Findings in the Long-Term Outcomes After Multisystem Inflammatory Syndrome in Children (MUSIC) Study. Circ Cardiovasc Imaging. 2025 Sep;18(9):e017420. doi: 10.1161/CIRCIMAGING.124.017420. Epub 2025 Apr 4.
Related trials for Multisystem Inflammatory Syndrome in Children (MIS-C)
RecruitingObservational study
Genetic Basis of SARS-CoV-2 Infection-Associated Multisystem Inflammatory Syndrome in Children (MIS-C)
MIS-C Associated With COVID-19
RecruitingObservational study
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension
RecruitingObservational study
Cardiovascular Assessment 5 Years After MIS-C
Multisystem Inflammatory Syndrome in Children (MIS-C), SARS-CoV-2 Infection
Active, not recruitingPhase 4
A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.
Myocarditis
RecruitingObservational study
Clinical Characteristics and Long Term Impact on Pediatric COVID-19 in Taiwan
Long Covid19, COVID-19 Pneumonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
33 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multisystem Inflammatory Syndrome in Children (MIS-C), run by Carelon Research at 33 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 33 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
worst-ever LV ejection fraction (time frame: hospital admission through 5 years post-hospitalization). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05287412, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.